Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical has reported Operating Leases over the past 7 years, most recently at $24.0 million for Q4 2025.

  • Quarterly Operating Leases fell 20.0% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, down 20.0% year-over-year, with the annual reading at $24.0 million for FY2025, 20.0% down from the prior year.
  • Operating Leases was $24.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $21.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $36.8 million in Q1 2021 and troughed at $14.8 million in Q2 2023.
  • The 5-year median for Operating Leases is $26.8 million (2022), against an average of $26.8 million.
  • Year-over-year, Operating Leases crashed 42.69% in 2023 and then skyrocketed 73.4% in 2024.
  • A 5-year view of Operating Leases shows it stood at $30.9 million in 2021, then tumbled by 35.89% to $19.8 million in 2022, then soared by 54.31% to $30.6 million in 2023, then dropped by 1.88% to $30.0 million in 2024, then decreased by 20.0% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Operating Leases are $24.0 million (Q4 2025), $21.7 million (Q3 2025), and $24.5 million (Q2 2025).